Patents by Inventor Thorsten Lamla

Thorsten Lamla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VIRAL CAPSID PROTEINS WITH SPECIFICITY TO HEART TISSUE CELLS
    Publication number: 20250325704
    Abstract: This invention generally relates to the field of somatic gene therapy by using viral vectors, and in particular adeno-associated virus (AAV) vectors for the treatment of inherited or acquired diseases. More specifically, the invention relates to a viral capsid protein that provide for a specific transduction of murine endothelial cells for treating or preventing a heart disease in a primate. The viral capsid protein was found to specifically bind to primate heart tissue cells, and in particular primate heart muscle cells, and can be used to provide for an efficient and selective transduction of primate cardiomyocytes and ensure heart tissue-specific expression of one or more transgenes in the primate. The invention further relates to a recombinant viral vector, preferably an AAV vector, which comprises a capsid with at least one transgene packaged in the capsid. The viral vector is suitable for the therapeutic treatment of a cardiac disorder or disease in a primate.
    Type: Application
    Filed: December 23, 2021
    Publication date: October 23, 2025
    Inventors: Thorsten Lamla, Dragica BLAZEVIC, Stefan MICHELFELDER, Matthias DÜCHS, Sebastian KREUZ, Achim SAUER, Florian MEIER, Birgit STIERSTORFER, Kai Christoph WOLLERT, Mortimer KORF-KLINGEBIEL
  • VIRAL VECTORS AND NUCLEIC ACIDS FOR USE IN THE TREATMENT OF ILD, PF-ILD AND IPF
    Publication number: 20240011033
    Abstract: Viral vector comprising: a capsid and a packaged nucleic acid, wherein the nucleic acid either augments the miRNA downregulated in a Bleomycin-induced lung fibrosis model or in an AAV-TGF?1-induced lung fibrosis model, or wherein the nucleic acid inhibits the miRNA up-regulated in a Bleomycin-induced lung fibrosis model or in an AAV-TGF?1-induced lung fibrosis model.
    Type: Application
    Filed: November 4, 2021
    Publication date: January 11, 2024
    Inventors: Sebastian Kreuz, Ludger Ickenstein, Marc Kaestle, Stephan Klee, Holger Klein, Thorsten Lamla, Benjamin Strobel
  • VIRAL VECTORS AND NUCLEIC ACIDS FOR USE IN THE TREATMENT OF ILD, PF-ILD AND IPF
    Publication number: 20230416738
    Abstract: Viral vector comprising: a capsid and a packaged nucleic acid, wherein the nucleic acid either augments the miRNA downregulated in a Bleomycin-induced lung fibrosis model or in an AAV-TGF #1-induced lung fibrosis model, or wherein the nucleic acid inhibits the miRNA up-regulated in a Bleomycin-induced lung fibrosis model or in an AAV-TGF #1-induced lung fibrosis model.
    Type: Application
    Filed: November 4, 2020
    Publication date: December 28, 2023
    Inventors: Sebastian Kreuz, Holger Klein, Benjamin Strobel, Stephan Klee, Thorsten Lamla, Marc Kaestle, Ludger Ickenstein
  • VIRAL VECTORS AND NUCLEIC ACIDS FOR USE IN THE TREATMENT OF ILD, PF-ILD AND IPF
    Publication number: 20230407303
    Abstract: Viral vector comprising: a capsid and a packaged nucleic acid, wherein the nucleic acid either augments the miRNA downregulated in a Bleomycin-induced lung fibrosis model or in an AAV-TGF?1-induced lung fibrosis model, or wherein the nucleic acid inhibits the miRNA up-regulated in a Bleomycin-induced lung fibrosis model or in an AAV-TGF?1-induced lung fibrosis model.
    Type: Application
    Filed: November 4, 2021
    Publication date: December 21, 2023
    Inventors: Sebastian Kreuz, Holger Klein, Benjamin Strobel, Stephan Klee, Thorsten Lamla, Marc Kaestle, Ludger Ickenstein
  • VIRAL VECTORS AND NUCLEIC ACIDS FOR USE IN THE TREATMENT OF PF-ILD AND IPF
    Publication number: 20220213503
    Abstract: Viral vector comprising: a capsid and a packaged nucleic acid, wherein the nucleic acid either augments the miRNA downregulated in a Bleomycin-induced lung fibrosis model or in an AAV-TGF?1-induced lung fibrosis model, or wherein the nucleic acid inhibits the miRNA up-regulated in a Bleomycin-induced lung fibrosis model or in an AAV-TGF?1-induced lung fibrosis model.
    Type: Application
    Filed: April 30, 2020
    Publication date: July 7, 2022
    Inventors: Sebastian Kreuz, Holger Klein, Benjamin Strobel, Stephan Klee, Thorsten Lamla, Marc Kaestle
  • Streptavidin-binding peptide
    Patent number: 8076452
    Abstract: The invention relates to novel streptavidin binding peptides.
    Type: Grant
    Filed: February 20, 2003
    Date of Patent: December 13, 2011
    Inventors: Volker A. Erdmann, Thorsten Lamla
  • Method for gene expression
    Patent number: 7247448
    Abstract: The invention relates to a method for gene expression in a cell-free transcription/translation system, the reaction solution containing all the components necessary for the transcription/translation mechanism, amino acids, nucleotides, metabolic components which provide energy and which are necessary for synthesis, and the proteins arising during translation being immobilized on a matrix.
    Type: Grant
    Filed: July 17, 2002
    Date of Patent: July 24, 2007
    Assignee: RiNA Netzwerk RNA-Technologien GmbH
    Inventors: Volker A. Erdmann, Thorsten Lamla, Wolfgang Stiege
  • Streptavidin-binding peptide
    Publication number: 20060106199
    Abstract: The invention relates to novel streptavidin binding peptides.
    Type: Application
    Filed: February 20, 2003
    Publication date: May 18, 2006
    Inventors: Volker Erdmann, Thorsten Lamla
  • Method for gene expression
    Publication number: 20050227312
    Abstract: The invention relates to a method for gene expression in a cell-free transcription/translation system, the reaction solution containing all the components necessary for the transcription/translation mechanism, amino acids, nucleotides, metabolic components which provide energy and which are necessary for synthesis, and the proteins arising during translation being immobilized on a matrix.
    Type: Application
    Filed: July 17, 2002
    Publication date: October 13, 2005
    Applicant: Rina Netzwerk RNA-Technologien GMBH
    Inventors: Volker Erdmann, Thorsten Lamla, Wolfgang Stiege